Related references
Note: Only part of the references are listed.Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors
Toshio Kuwai et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer
Xiao-Hua Zhang et al.
BMC CANCER (2008)
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions
Alessandro Morabito et al.
ONCOLOGIST (2006)
Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas
Yukihiro Hiraishi et al.
PATHOLOGY & ONCOLOGY RESEARCH (2006)
Overexpression of platelet-derived growth factor receptor α in endothelial cells of hepatocellular carcinoma associated with high metastatic potential
T Zhang et al.
CLINICAL CANCER RESEARCH (2005)
Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis
R Cressey et al.
BMC CANCER (2005)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer
KJ O'Byrne et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
